X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (145) 145
index medicus (141) 141
male (109) 109
female (106) 106
middle aged (85) 85
adult (79) 79
hematology (73) 73
aged (70) 70
abridged index medicus (51) 51
expression (36) 36
oncology (34) 34
aged, 80 and over (27) 27
multiple myeloma (23) 23
aids/hiv (21) 21
treatment outcome (21) 21
immunology (19) 19
immunophenotyping (18) 18
leukemia (18) 18
activation (17) 17
bortezomib (17) 17
killer cells, natural - immunology (17) 17
multiple myeloma - drug therapy (17) 17
flow cytometry (16) 16
cells, cultured (15) 15
care and treatment (14) 14
follow-up studies (14) 14
t-lymphocytes - immunology (14) 14
phenotype (13) 13
prognosis (13) 13
apoptosis (12) 12
chemotherapy (12) 12
cytotoxicity, immunologic (12) 12
disease (12) 12
interleukin-2 - pharmacology (12) 12
lymphocytes (12) 12
lymphoproliferative disorders - immunology (12) 12
respiratory system (12) 12
therapy (12) 12
antineoplastic combined chemotherapy protocols - therapeutic use (11) 11
disease-free survival (11) 11
hematology, oncology and palliative medicine (11) 11
lenalidomide (11) 11
lung - immunology (11) 11
natural-killer-cells (11) 11
retrospective studies (11) 11
survival (11) 11
analysis (10) 10
cells (10) 10
interleukin-2 (10) 10
killer cells, natural - pathology (10) 10
physiological aspects (10) 10
proliferation (10) 10
t cells (10) 10
thalidomide - administration & dosage (10) 10
adolescent (9) 9
development and progression (9) 9
dexamethasone (9) 9
lymphoproliferative disease (9) 9
phosphorylation (9) 9
recurrence (9) 9
thalidomide - analogs & derivatives (9) 9
transplantation (9) 9
tumor-necrosis-factor (9) 9
animals (8) 8
antineoplastic combined chemotherapy protocols - administration & dosage (8) 8
bronchoalveolar lavage fluid - cytology (8) 8
chronic lymphocytic-leukemia (8) 8
clinical neurology (8) 8
hiv infections - immunology (8) 8
kaplan-meier estimate (8) 8
leukemia, lymphocytic, chronic, b-cell - pathology (8) 8
lung (8) 8
lymphocytes - immunology (8) 8
neutropenia (8) 8
t-cells (8) 8
thalidomide - therapeutic use (8) 8
tumor cells, cultured (8) 8
acquired immunodeficiency syndrome - immunology (7) 7
apoptosis - drug effects (7) 7
bronchoalveolar lavage (7) 7
cancer (7) 7
cell biology (7) 7
identification (7) 7
leukemia, large granular lymphocytic - pathology (7) 7
leukemia, lymphocytic, chronic, b-cell - metabolism (7) 7
lung - pathology (7) 7
lymphoproliferative disease of granular lymphocytes (7) 7
lymphoproliferative disorders - blood (7) 7
lymphoproliferative disorders - pathology (7) 7
molecular sequence data (7) 7
research (7) 7
signal transduction (7) 7
t-lymphocytes - metabolism (7) 7
thalidomide - adverse effects (7) 7
alveolar macrophages (6) 6
antibodies, monoclonal (6) 6
antigens, cd - analysis (6) 6
antimitotic agents (6) 6
antineoplastic agents (6) 6
antineoplastic agents - administration & dosage (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 04/2013, Volume 31, Issue 11, pp. 1442 - 1449
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2014, Volume 32, Issue 7, pp. 634 - 640
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2011, Volume 29, Issue 8, pp. 986 - 993
Purpose In patients with myeloma, thalidomide significantly improves outcomes but increases the risk of thromboembolic events. In this randomized, open-label,... 
LOW-DOSE WARFARIN | DEXAMETHASONE | THERAPY | VENOUS THROMBOEMBOLISM | ONCOLOGY | DEEP-VEIN THROMBOSIS | PREDNISONE PLUS THALIDOMIDE | BORTEZOMIB | STEM-CELL TRANSPLANTATION | ELDERLY-PATIENTS | MELPHALAN | Multiple Myeloma - mortality | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Warfarin - adverse effects | Male | Antineoplastic Agents - administration & dosage | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Warfarin - therapeutic use | Fibrinolytic Agents - adverse effects | Multiple Myeloma - drug therapy | Thromboembolism - prevention & control | Time Factors | Aspirin - adverse effects | Fibrinolytic Agents - therapeutic use | Cardiovascular Diseases - mortality | Female | Aspirin - therapeutic use | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Cardiovascular Diseases - etiology | Risk Assessment | Multiple Myeloma - complications | Risk Factors | Anticoagulants - therapeutic use | Treatment Outcome | Thromboembolism - etiology | Thromboembolism - mortality | Thalidomide - administration & dosage | Anticoagulants - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Italy | Aged | Hemorrhage - chemically induced | Index Medicus
Journal Article
Journal Article
Blood, ISSN 0006-4971, 07/2012, Volume 120, Issue 1, pp. 9 - 19
Journal Article
PLoS ONE, ISSN 1932-6203, 09/2013, Volume 8, Issue 9, pp. e75280 - e75280
CK2 is a pivotal pro-survival protein kinase in multiple myeloma that may likely impinge on bortezomib-regulated cellular pathways. In the present study, we... 
CANCER-CELLS | ACTIVATION | SIGNALING PATHWAY | INDUCED APOPTOSIS | PHOSPHORYLATION | MULTIDISCIPLINARY SCIENCES | THERAPEUTIC TARGET | TRANSCRIPTION | PROLIFERATION | PROTEASOME INHIBITORS | EXPRESSION | Immunohistochemistry | Boronic Acids - metabolism | Apoptosis - drug effects | Humans | Molecular Sequence Data | NF-kappa B - metabolism | DNA Primers - genetics | Pyrazines - metabolism | Casein Kinase II - genetics | Leukocytes, Mononuclear | Multiple Myeloma - drug therapy | RNA Interference | Adenosine Triphosphate - metabolism | Base Sequence | Real-Time Polymerase Chain Reaction | STAT3 Transcription Factor - metabolism | Bortezomib | Casein Kinase II - antagonists & inhibitors | Lymphoma, Mantle-Cell - drug therapy | Blotting, Western | Analysis of Variance | Signal Transduction - drug effects | Cell Line, Tumor | Signal Transduction - physiology | Pyrazines - pharmacology | Naphthyridines - pharmacology | Boronic Acids - pharmacology | Protein kinase C | Transcription factors | Phosphorylation | Laboratories | Toxicity | Multiple myeloma | Cytotoxicity | Kinases | Casein kinase II | Proteins | Signal transduction | Mitochondria | Immunology | Pathways | Cascades | Bone marrow | Inhibition | Mantle | Stresses | NF-κB protein | Cell survival | Cytokines | Hematology | Stat3 protein | Hsp70 protein | Tumor cell lines | Survival | Lymphoma | Stress | Medicine | Pathology | Signaling | Inhibitors | Lymphocytes B | Cell death | Cell lines | Mantle cell lymphoma | Interferon | Lymphomas | Endoplasmic reticulum | Tumors | Apoptosis | Index Medicus
Journal Article
Journal Article
ANNALS OF HEMATOLOGY, ISSN 0939-5555, 06/2016, Volume 95, Issue 7, pp. 1107 - 1114
Journal Article